在一名接受厄洛替尼和奥希替尼治疗的肺腺癌患者的循环肿瘤DNA中检测到新型SPECC1L-MET融合基因。 - Suppr

Suppr

超能文献

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.

作者信息

Nelson Annie W, Schrock Alexa B, Pavlick Dean C, Ali Siraj M, Atkinson Emily C, Chachoua Abraham

机构信息

Foundation Medicine, Inc., Cambridge, Massachusetts.

出版信息

J Thorac Oncol. 2019 Feb;14(2):e27-e29. doi: 10.1016/j.jtho.2018.10.160.

DOI:10.1016/j.jtho.2018.10.160

PMID:30683294

Abstract

摘要

相似文献

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.在一名接受厄洛替尼和奥希替尼治疗的肺腺癌患者的循环肿瘤DNA中检测到新型SPECC1L-MET融合基因。

J Thorac Oncol. 2019 Feb;14(2):e27-e29. doi: 10.1016/j.jtho.2018.10.160.

Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.厄洛替尼/克唑替尼联合治疗一名原发性EGFR突变加继发性MET扩增且获得新型克唑替尼耐药突变MET G1108C的肺腺癌患者。

Ann Oncol. 2017 Oct 1;28(10):2622-2624. doi: 10.1093/annonc/mdx324.

MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.MET 扩增导致接受厄洛替尼治疗的 EGFR 突变型肺癌对奥希替尼的异质性反应。

Cancer Sci. 2020 Oct;111(10):3813-3823. doi: 10.1111/cas.14593. Epub 2020 Sep 1.

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung.一名原发性EGFR突变型肺腺癌合并原发性c-met扩增型肺腺癌患者对克唑替尼/厄洛替尼联合治疗的反应

J Thorac Oncol. 2015 May;10(5):e23-e25. doi: 10.1097/JTO.0000000000000448.

Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report.在携带MET扩增的EGFR突变肺腺癌中联合使用克唑替尼抑制EGFR和MET：简要报告

Clin Lung Cancer. 2020 Nov;21(6):e601-e606. doi: 10.1016/j.cllc.2020.05.015. Epub 2020 May 23.

GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.GOPC-ROS1重排作为肺腺癌对奥希替尼获得性耐药机制及对克唑替尼联合治疗敏感的机制

J Thorac Oncol. 2018 Jul;13(7):e114-e116. doi: 10.1016/j.jtho.2018.02.005.

Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma.在厄洛替尼耐药的肺腺癌中，MET基因拷贝数的异质性和表皮生长因子受体（EGFR）突变导致原发灶和转移灶对克唑替尼产生不一致的反应。

Lung Cancer. 2018 Oct;124:317-319. doi: 10.1016/j.lungcan.2018.03.016. Epub 2018 Mar 17.

Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.液体活检检测到MET扩增且对EGFR酪氨酸激酶抑制产生继发性耐药的肺癌患者对克唑替尼和奥希替尼联合治疗的反应

J Thorac Oncol. 2018 Sep;13(9):e169-e172. doi: 10.1016/j.jtho.2018.04.007.

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.奥希替尼耐药的 EGFR 突变型肺癌对第一代可逆性 EGFR 抑制剂敏感，但在临床前模型和临床样本中最终会获得 EGFR T790M/C797S 耐药突变。

J Thorac Oncol. 2019 Nov;14(11):1995-2002. doi: 10.1016/j.jtho.2019.07.016. Epub 2019 Aug 1.

Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.MET 扩增型非小细胞肺癌患者奥希替尼耐药的下一代测序临床分析。

Lung Cancer. 2018 Apr;118:105-110. doi: 10.1016/j.lungcan.2018.02.007. Epub 2018 Feb 13.

引用本文的文献

Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and fusion.病例报告：一名非小细胞肺癌伴融合患者因MET Y1230H突变获得对克唑替尼的耐药性。

Front Oncol. 2024 Apr 16;14:1370901. doi: 10.3389/fonc.2024.1370901. eCollection 2024.

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.在转移性致癌基因驱动的非小细胞肺癌患者中，通过联合使用母代和MET酪氨酸激酶抑制剂治疗获得性MET耐药的疗效和安全性。

JTO Clin Res Rep. 2024 Jan 18;5(2):100637. doi: 10.1016/j.jtocrr.2024.100637. eCollection 2024 Feb.

Targeting MET in NSCLC: An Ever-Expanding Territory.非小细胞肺癌中靶向MET：一个不断扩展的领域。

JTO Clin Res Rep. 2024 Jan 3;5(2):100630. doi: 10.1016/j.jtocrr.2023.100630. eCollection 2024 Feb.

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.非小细胞肺癌对表皮生长因子受体酪氨酸激酶抑制剂的耐药性：从分子机制到新治疗策略的临床应用

Pharmaceutics. 2023 May 27;15(6):1604. doi: 10.3390/pharmaceutics15061604.

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options.奥希替尼耐药：分子机制与新出现的治疗选择

Cancers (Basel). 2023 Jan 30;15(3):841. doi: 10.3390/cancers15030841.

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。

J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.

BCL6-SPECC1L: A Novel Fusion Gene in Nasopharyngeal Carcinoma.BCL6-SPECC1L：鼻咽癌中的一种新融合基因。

Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221139981. doi: 10.1177/15330338221139981.

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon G719D/L861Q mutations and an acquired novel - fusion.病例报告：一名具有罕见的双重G719D/L861Q突变和获得性新型融合的肺腺癌患者对埃克替尼联合克唑替尼产生持久部分缓解。

Front Oncol. 2022 Jul 26;12:911362. doi: 10.3389/fonc.2022.911362. eCollection 2022.

Cytospin-A Regulates Colorectal Cancer Cell Division and Migration by Modulating Stability of Microtubules and Actin Filaments.细胞离心涂片仪-A通过调节微管和肌动蛋白丝的稳定性来调控结肠癌细胞的分裂和迁移。

Cancers (Basel). 2022 Apr 14;14(8):1977. doi: 10.3390/cancers14081977.

Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel Fusion.病例报告：一名新型融合基因阳性的非小细胞肺癌患者对克唑替尼产生显著反应

Front Oncol. 2022 Feb 14;12:804330. doi: 10.3389/fonc.2022.804330. eCollection 2022.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验